Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Xilio Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 33
- +2 vs. Q2 2024
- Shares held
- 16.0M
- +1.51M (+10.5%) vs. Q2 2024
- Total value
- $12.6M
- −$1.10M (−8.1%) vs. Q2 2024
- New holders
- 6
- 8 more added
- Sold out
- 4
- 4 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 4,566,817 | $3.60M | 0.37% | +781,367+20.6% | Added |
| Rock Springs Capital Management LP | 3,003,259 | $2.37M | 0.08% | 00.0% | Unchanged |
| Morgan Stanley | 1,522,102 | $1.20M | 0.00% | +409,362+36.8% | Added |
| Takeda Pharmaceutical Co Ltd | 1,475,121 | $1.16M | 3.06% | 00.0% | Unchanged |
| RiverVest Venture Management LLC | 1,441,444 | $1.14M | 16.60% | 00.0% | Unchanged |
| FMR LLC | 1,395,853 | $1.10M | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 902,531 | $711.2K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 338,192 | $266.4K | 0.00% | +155,337+85.0% | Added |
| Balyasny Asset Management LLC | 272,486 | $214.6K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 266,300 | $209.8K | 0.00% | −28,700−9.7% | Reduced |
| FIL Ltd | 218,705 | $172.3K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 75,624 | $59.6K | 0.00% | +75,624 | New |
| Bridgeway Capital Management, LLC | 71,081 | $56.0K | 0.00% | 00.0% | Unchanged |
| SevenBridge Financial Group, LLC | 41,000 | $44.7K | 0.01% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 44,445 | $35.0K | 0.00% | +31,174+234.9% | Added |
| State Street Corp | 43,390 | $34.2K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 39,208 | $30.9K | 0.00% | 00.0% | Unchanged |
| Raymond James & Associates | 38,825 | $30.6K | 0.00% | 00.0% | Unchanged |
| Engineers Gate Manager LP | 32,752 | $25.8K | 0.00% | +32,752 | New |
| Mariner, LLC | 25,317 | $19.9K | 0.00% | +25,317 | New |
| XTX Topco Ltd | 23,862 | $18.8K | 0.00% | −9,427−28.3% | Reduced |
| Millennium Management LLC | 20,655 | $16.3K | 0.00% | +8,450+69.2% | Added |
| Avantax Planning Partners, Inc. | 20,483 | $16.1K | 0.00% | −4,517−18.1% | Reduced |
| Steward Partners Investment Advisory, LLC | 20,000 | $15.8K | 0.00% | +20,000 | New |
| UBS Group AG | 15,733 | $12.4K | 0.00% | +15,532+7,727.4% | Added |
| Two Sigma Investments, LP | 10,389 | $8.18K | 0.00% | +10,389 | New |
| Dunhill Financial, LLC | 10,274 | $8.09K | 0.00% | 00.0% | Unchanged |
| Pinnacle Financial Group, LLC | 10,000 | $7.88K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 5,616 | $4.42K | 0.00% | +1,409+33.5% | Added |
| Key Financial Inc | 830 | $654 | 0.00% | 00.0% | Unchanged |
| Private Wealth Management Group, LLC | 310 | $245 | 0.00% | +310 | New |
| Bank of America Corp | 266 | $209 | 0.00% | −426−61.6% | Reduced |
| JPMorgan Chase & Co | 75 | $59 | 0.00% | +16+27.1% | Added |
| Charles Schwab Investment Management Inc | 0 | $0 | 0.00% | −11,925−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −1,500−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −366−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |